Treatment Center Registration

AMVUTTRA® Online Treatment Center Directory Registration

Include your center(s)

Fill out the form below to have your treatment center included in our online directory for patients and healthcare professionals.

*Indicates required field.
Please correct the errors highlighted in red
Hours of Operation*
Container Bottom
The AMVUTTRA Treatment Center Directory will offer the user the opportunity to locate and contact a treatment site of care. The data collected in connection with the AMVUTTRA Treatment Center Directory is for informational purposes only. No fees or other remuneration have been or will be exchanged for a treatment center’s inclusion in this database. Inclusion of centers in this database will be based on opt-in approval by authorized personnel for those sites listed. Alnylam Pharmaceuticals is not affiliated with, and inclusion in this database does not represent an endorsement of, recommendation for, or referral to, the treatment centers listed in this database. Likewise, participating treatment centers do not necessarily endorse the use of any Alnylam Pharmaceuticals products.

Important Safety Information and Indication

Important Safety Information

Reduced Serum Vitamin A Levels and Recommended Supplementation

AMVUTTRA® (vutrisiran) treatment leads to a decrease in serum vitamin A levels.

Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with AMVUTTRA were pain in extremity (15%), arthralgia (11%), dyspnea (7%), and vitamin A decreased (7%).


AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about AMVUTTRA, please see the full Prescribing Information.